Regeneron Pharmaceuticals, Inc.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops, manufactures and markets antibody-based medicines for ophthalmology, oncology, immunology, infectious disease and rare disorders. Founded in 1988 and headquartered in Tarrytown, New York, Regeneron uses its proprietary VelociSuite technologies to discover fully human monoclonal antibodies and other therapeutic proteins. Its FDA-approved products include EYLEA, Dupixent, Libtayo, Praluent and Kevzara, while a broad pipeline addresses asthma, cancer, Ebola, COVID-19 and other diseases. The company operates research, manufacturing and clinical facilities across the United States and collaborates with Sanofi, Bayer and other partners worldwide.